Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

peptide drug conjugate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (6) Antibody-Drug Conjugates (ADCs) (3) Drug-Linker Conjugates for ADC (14) Peptide-Drug Conjugates (PDCs) (10) Radionuclide-Drug Conjugates (RDCs) (9) ADC Payload (3) Apoptosis (2) Bacterial (2) Biochemical Assay Reagents (15) Carbonic Anhydrase (1) CXCR (4) DNA/RNA Synthesis (1) E-Selectin (1) EGFR (2) Ephrin Receptor (1) Epigenetic Reader Domain (1) Eukaryotic Initiation Factor (eIF) (1) Exosomes (3) Folate Receptor (FR) (3) HSP (2) IFNAR (1) Integrin (1) Isotope-Labeled Compounds (5) LDLR (1) Liposome (16) Microtubule/Tubulin (2) MMP (1) Nectin-4 (1) PERK (1) Prostaglandin Receptor (1) PSMA (1) Somatostatin Receptor (1) Topoisomerase (2) Transferrin Receptor (1) TRP Channel (1) YAP (1)
By Research Areas:	Cancer (54) Cardiovascular Disease (5) Infection (2) Inflammation/Immunology (1) Neurological Disease (5)
Click Chemistry:	BCN (1)
Oligonucleotides:	Pegylated Lipids (10) Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: Peptide-Drug Conjugates (PDCs) Drug Intermediate Drug Isomer Drug Derivative Drug Metabolite RXFP Receptor Formyl Peptide Receptor (FPR) Antibody-Drug Conjugates (ADCs) Natriuretic Peptide Receptor (NPR) Radionuclide-Drug Conjugates (RDCs) Drug-Linker Conjugates for ADC Connective Peptide CGRP Receptor Amyloid-β ADC Linker

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-13631E

Deruxtecan Maximum Cited Publications 25 Publications Verification MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-138298

Trastuzumab deruxtecan (solution) 5 Publications Verification T-DXd (solution); DS-8201 (solution); DS-8201a (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-*human epidermal growth factor receptor 2 (HER2) antibody-drug* conjugate (ADC)*. Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate* for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-138298A

Trastuzumab deruxtecan 5 Publications Verification T-DXd; DS-8201; DS-8201a	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (DS-8201a) is an anti-*human epidermal growth factor receptor 2 (HER2) antibody-drug* conjugate (ADC)*. Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate* for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-106244

DOTATATE 3 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-15582

Auristatin E	Microtubule/Tubulin ADC Payload	Cancer
Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .

HY-150241

DOPE-NHS	Exosomes Biochemical Assay Reagents Liposome	Others
DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .

HY-125586

β-Amanitin	DNA/RNA Synthesis ADC Payload	Cancer
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-P4073

ANG1005 GRN1005; Paclitaxel trevatide	Peptide-Drug Conjugates (PDCs) LDLR	Cancer
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244A

DOTATATE acetate 3 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-13631ES4

Deruxtecan-d5 MC-GGFG-DXD-d₅	Isotope-Labeled Compounds Drug-Linker Conjugates for ADC	Cancer
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631EG

Deruxtecan MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-W071967

Alloc-Val-Ala-pAB	ADC Linker	Cancer
Alloc-Val-Ala-PAB is a peptide cleavable linker used in the synthesis of antibody-drug conjugates (ADCs). The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.

HY-P11099

Cys-LT7	Transferrin Receptor	Neurological Disease Cancer
Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma .

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand *peptide*-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-172279A

DSPE-PEG2000-TAT	Liposome	Cancer
DSPE-PEG2000-TAT is a cell-penetrating peptide-modified PEGylated phospholipid conjugate and cellular uptake enhancer. DSPE-PEG2000-TAT forms via conjugation of Cys-TAT to DSPE-PEG2000-Mal. DSPE-PEG2000-TAT enhances liposomal cellular uptake and siRNA transfection efficiency in glomerular mesangial and macrophage cells. DSPE-PEG2000-TAT can be used for drug delivery .

HY-160807

DBM-GGFG-NH-O-CO-Exatecan	Drug-Linker Conjugates for ADC	Cancer
DBM-GGFG-NH-O-CO-Exatecan (Example 4, Compound 14) is a conjugate of an ADC drug toxin molecule and a linker. DBM-GGFG-NH-O-CO-Exatecan is a complete antibody-drug conjugate intermediate that integrates a potent camptothecin-based toxin, a cleavable peptide linker (GGFG), and a reactive terminus that can directly conjugate to antibodies .

HY-P2218

Anditixafortide	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3436

WLSEAGPVVTVRALRGTGSW	Exosomes	Cardiovascular Disease
WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .

HY-19813A

mDPR-Val-Cit-PAB-MMAE TFA	Drug-Linker Conjugates for ADC	Cancer
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition ^{[1] ^.}

HY-44177

Val-Cit-PAB-MMAF sodium	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAF sodium is a drug-Linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-13631ES3

Deruxtecan-d2 MC-GGFG-DXD-d₂	Drug-Linker Conjugates for ADC Isotope-Labeled Compounds	Others
Deruxtecan-d₂ is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-P10740

CBP-1018	Peptide-Drug Conjugates (PDCs) PSMA Folate Receptor (FR)	Cancer
CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer .

HY-15582S

Auristatin E-d8	Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload	Cancer
Auristatin E-d₈ is the deuterium labeled Auristatin E (HY-15582). Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .

HY-P4123

TAT (47-57) GGG-Cys(Npys)	MMP	Cardiovascular Disease Inflammation/Immunology Cancer
TAT (47-57) GGG-Cys (Npys) is a cell-penetrating peptide and delivery carrier derived from TAT. TAT (47-57) GGG-Cys (Npys) facilitates the translocation of conjugated drug molecules across cell membranes. TAT (47-57) GGG-Cys (Npys) acts as a delivery carrier for MT1-MMP inhibitors. TAT (47-57) GGG-Cys (Npys) is applicable to research on diseases associated with MT1-MMP activity, such as cancer, arthritis, heart disease, and vascular disorders .

HY-129360

Ala-Ala-Asn-PAB	ADC Linker	Cancer
Ala-Ala-Asn-PAB is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .

HY-153395

PH-HG-005-5	Drug-Linker Conjugates for ADC	Cancer
PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .

HY-101909

Val-Cit-PAB-MMAF	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAF is a drug-Linker conjugate for ADC. Val-Cit-PAB-MMAF is composed of an ADC linker (peptide Val-Cit-PAB) and a potent microtubule polymerization inhibitor MMAF (HY-15579) .

HY-172273A

DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY	Liposome	Cancer
DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .

HY-13631ES

Deruxtecan-d4 MC-GGFG-DXD-d₄	Drug-Linker Conjugates for ADC Isotope-Labeled Compounds	Others
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-P10895

HR97 TFA	Biochemical Assay Reagents	Others
HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops HR97-SunitiGel. The peptide-drug conjugate in HR97-SunitiGel can provide sustained ocular drug delivery .

HY-147021

MC-Val-D-Cit-PAB-PNP	ADC Linker	Cancer
MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.

HY-158199

BCN-HS-PEG2-bis(PNP)	ADC Linker	Cancer
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .

HY-172273

DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY	Liposome	Cancer
DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-13631ES2

Deruxtecan-d4-1 MC-GGFG-DXD-d₄-1	Drug-Linker Conjugates for ADC Isotope-Labeled Compounds	Others
Deruxtecan-d₄-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-178489

BGC1614	Nectin-4	Cancer
BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an K_D of 3.859 × 10 ^-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .

HY-P10757

DTX-P7	Peptide-Drug Conjugates (PDCs) Apoptosis HSP Eukaryotic Initiation Factor (eIF) PERK	Cancer
DTX-P7 is a **peptide-drug conjugate**. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90 .

HY-172273C

DSPE-PEG3400-M2pep	Liposome	Cancer
DSPE-PEG3400-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG3400-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .

HY-172465

DSPE-PEG5000-cRGD	Liposome Integrin	Cardiovascular Disease Cancer
DSPE-PEG5000-cRGD is a PEG conjugate composed of DSPE and the αvβ3-targeting peptide (cRGD). The cRGD peptide specifically binds to αvβ3 on the surface of various cancer cells and neovascular cells. DSPE-PEG5000-cRGD is applicable for research on drug delivery, cancer and vascular diseases .

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10760

PhAc-ALGP-Dox	Peptide-Drug Conjugates (PDCs)	Cancer
PhAc-ALGP-Dox, a **peptide-drug conjugate**, is a novel anticancer prodrug, with IC₅₀ values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

HY-P11018

(123B9)2-L2-PTX	Peptide-Drug Conjugates (PDCs) Ephrin Receptor	Cancer
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .

HY-129360A

Ala-Ala-Asn-PAB TFA	ADC Linker	Cancer
Ala-Ala-Asn-PAB TFA is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .

HY-128937

EC1454	Liposome Folate Receptor (FR)	Cancer
EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy .

Cat. No.	상품명	Category	Target	Chemical Structure

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Animals Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Others
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

Cat. No.	상품명	Chemical Structure

HY-13631ES4

Deruxtecan-d5
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES3

Deruxtecan-d2
Deruxtecan-d₂ is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-15582S

Auristatin E-d8

Auristatin E-d₈ is the deuterium labeled Auristatin E (HY-15582). Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .

HY-13631ES

Deruxtecan-d4
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES2

Deruxtecan-d4-1
Deruxtecan-d₄-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

Targets Recommended: Peptide-Drug Conjugates (PDCs) Drug Intermediate Drug Isomer Drug Derivative Drug Metabolite RXFP Receptor Formyl Peptide Receptor (FPR) Antibody-Drug Conjugates (ADCs) Natriuretic Peptide Receptor (NPR) Radionuclide-Drug Conjugates (RDCs) Drug-Linker Conjugates for ADC Connective Peptide CGRP Receptor Amyloid-β ADC Linker

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-13631EG

Deruxtecan MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

peptide drug conjugate

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products